The FDA Puts a Halt to Trial for SGT-001, A Treatment in Development for Duchenne Muscular Dystrophy
According to a story from raredr.com, the FDA had to order the cessation of Phase II/III trials for the microdystrophin transfer therapy SGT-001, which was in development for the treatment…